We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $8.17B
1-Year Est. Return 68.82%
This Fund
S&P 500
This Quarter Est. Return
+20.49%
1 Year Est. Return
+68.82%
3 Year Est. Return
+79.68%
5 Year Est. Return
+64.24%
10 Year Est. Return
+259.8%
AUM
$1.73B
AUM Growth
+$225M
Cap. Flow
+$22.1M
Cap. Flow %
1.27%
Top 10 Hldgs %
47.96%
Holding
98
New
32
Increased
17
Reduced
16
Closed
27

Top Buys

Rank Stock Value
1
SUPN icon
Supernus Pharmaceuticals
SUPN
+$41.6M
2
WSM icon
Williams-Sonoma
WSM
+$31.1M
3
DECK icon
Deckers Outdoor
DECK
+$29.3M
4
BMY icon
Bristol-Myers Squibb
BMY
+$28.6M
5
AZO icon
AutoZone
AZO
+$28.5M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$50.8M
2
ENR icon
Energizer
ENR
+$34.9M
3
FL
Foot Locker
FL
+$26.5M
4
DPLO
DIPLOMAT PHARMACY, INC.
DPLO
+$26.5M
5
TGT icon
Target
TGT
+$25.7M

Sector Composition

Rank Sector Weight
1 Healthcare 45.34%
2 Miscellaneous 28.01%
3 Consumer Discretionary 17.1%
4 Consumer Staples 5.85%
5 Technology 2.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VYGR icon
26
Voyager Therapeutics
VYGR
$214M
$22.7M 1.31%
1,624,000
+528,000
+48% +$7.67M
KHC icon
27
Kraft Heinz
KHC
$29.7B
$22.2M 1.28%
690,000
-810,000
-54% -$24.5M
EL icon
28
Estee Lauder
EL
$36.9B
$20.7M 1.19%
+100,000
New +$19.4M
QSR icon
29
Restaurant Brands International
QSR
$27.3B
$19.9M 1.15%
312,850
+132,850
+74% +$8.89M
LULU icon
30
lululemon athletica
LULU
$11.4B
$19.4M 1.12%
83,700
-51,300
-38% -$10.9M
CPRX
31
DELISTED
Catalyst Pharmaceutical
CPRX
$19.1M 1.1%
+5,100,000
New +$23.8M
KPRX icon
32
Kiora Pharmaceuticals
KPRX
$11.3M
$18M 1.04%
4,979
– –
RL icon
33
Ralph Lauren
RL
$20.8B
$17.8M 1.03%
152,168
-79,832
-34% -$8.41M
MRTX
34
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$15.5M 0.89%
+120,000
New +$11.6M
TWNK
35
DELISTED
Hostess Brands, Inc. Class A Common Stock
TWNK
$14.9M 0.86%
1,028,000
+448,000
+77% +$6.09M
QGEN icon
36
Qiagen
QGEN
$8.76B
$14.9M 0.86%
+414,944
New +$15.4M
MDGL icon
37
Madrigal Pharmaceuticals
MDGL
$12.4B
$14.6M 0.84%
160,000
+52,000
+48% +$5.04M
ORLY icon
38
O'Reilly Automotive
ORLY
$69.4B
$14.5M 0.83%
495,000
-517,500
-51% -$14.8M
VRTX icon
39
Vertex Pharmaceuticals
VRTX
$134B
$14.2M 0.82%
65,000
+35,000
+117% +$7.08M
MNK
40
CALL
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$14M 0.81%
40,000
– –
TJX icon
41
TJX Companies
TJX
$141B
$12.9M 0.74%
+211,000
New +$12.5M
KSS icon
42
Kohl's
KSS
$2.12B
$12.7M 0.73%
+250,000
New +$12.7M
CPRI icon
43
Capri Holdings
CPRI
$1.49B
$12.5M 0.72%
+326,611
New +$11.3M
FIVE icon
44
Five Below
FIVE
$14B
$11.6M 0.67%
+90,457
New +$11.3M
WBT
45
DELISTED
Welbilt, Inc.
WBT
$11.3M 0.65%
724,000
-1,368,000
-65% -$23.4M
UTHR icon
46
United Therapeutics
UTHR
$21.5B
$11.3M 0.65%
128,000
-102,000
-44% -$8.98M
BJ icon
47
BJs Wholesale Club
BJ
$11.4B
$10.8M 0.62%
+475,746
New +$11.8M
MNK
48
DELISTED
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
$9.35M 0.54%
+2,678,000
New +$8.36M
PRTK
49
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$9.14M 0.53%
2,268,000
+696,000
+44% +$2.41M
CRSP icon
50
CRISPR Therapeutics
CRSP
$5.31B
$9.01M 0.52%
148,000
-116,000
-44% -$6.33M
1
2
3 4

Similar funds

MWM
Mission Wealth Management Santa Barbara, California $8.18B AUM 28.28% 1-Year Est. Return
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
FWCM
Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return
SC
Saturna Capital Bellingham, Washington $8.19B AUM 42.01% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
EHC
Everett Harris & Co Los Angeles, California $8.14B AUM 14.79% 1-Year Est. Return
BIM
Bridges Investment Management Omaha, Nebraska $8.22B AUM 21.38% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return

Armistice Capital's Q4 2019 Portfolio in Review

As of Q4 2019, Armistice Capital held 98 positions worth $1.73B, up 15% from $1.51B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital's Q4 2019 filing shows 32 new, 17 increased, 16 reduced and 27 closed positions. Its largest new stake was Supernus Pharmaceuticals: 1,712,000 shares worth $40.6M. The largest sale was Celgene Corp, an estimated $50.8M.

By sector, the portfolio is most concentrated in Healthcare at 45% of assets, up from 42% a quarter earlier, followed by Miscellaneous and Consumer Discretionary.

  • Armistice Capital's largest Q4 2019 buy was Supernus Pharmaceuticals: 1,712,000 shares worth $40.6M.
  • Armistice Capital added most to PTC Therapeutics in Q4 2019, an estimated $26.4M increase.
  • Armistice Capital's biggest Q4 2019 reduction was Kraft Heinz, cutting an estimated $24.5M.
  • Armistice Capital fully exited Celgene Corp in Q4 2019, selling an estimated $50.8M.
  • Armistice Capital's ten largest holdings make up 48% of its $1.73B portfolio in Q4 2019.
  • Armistice Capital opened 32 new positions and closed 27 in Q4 2019.
  • Armistice Capital's portfolio value rose 15% quarter-over-quarter to $1.73B.

Based on Armistice Capital's 13F filing for Q4 2019, filed 14 Feb 2020.